GeneNews, Cobalt Healthcare Buy Out HDL's Stake in CLIA Lab JV
News May 20, 2015
GeneNews today said that it has entered into a purchase agreement with Cobalt Healthcare Consultants to acquire Health Diagnostic Laboratory's stake in Innovative Diagnostic Laboratory, a joint venture established in 2013 by the three partners.
GeneNews and Cobalt Healthcare Consultants are buying HDL's 33 percent stake in IDL for $4 million. The acquisition gives GeneNews and Cobalt each a 50 percent stake in IDL, which was established as a jointly owned CLIA lab to develop and increase the adoption of GeneNews' ColonSentry colorectal cancer test in the US.
Enzo Biochem has the rights to commercialize the test in New York and New Jersey.
As part of the 2013 deal, Toronto-based GeneNews granted IDL an exclusive license for certain technology related to ColonSentry for development and commercialization in the US, excluding New York and New Jersey. GeneNews Executive Chairman James Howard-Tripp said in a statement today that the firm will continue to grow IDL through internal pipeline development, and "increasing our ownership interest in IDL will provide us with greater management and cost control, more direct input, and a higher share of the joint venture's economics."
He added that GeneNews intends to increase its ownership stake in IDL based on future opportunities, and confirmed to GenomeWeb that Cobalt is the previously unnamed sales organization that GeneNews and HDL partnered with to create IDL.
As part of the deal, GeneNews and Cobalt will each pay HDL $1 million in cash. Each firm will also issue a one-year secured promissory note in the principal amount of $1 million to HDL.
Howard-Tripp said that moving ahead the focus will be on expanding IDL's sales effort "by reestablishing growth trends of existing tests," increasing the lab's test menu, and improving revenue collections.
Cellular Valve Structure Opens Up Potential Novel TherapiesNews
Biochemists have determined the detailed structure of a volume-regulated chloride channel. This cellular valve is activated in response to swelling to prevent the cell from bursting. The protein also plays an important role in the uptake of chemotherapeutics and the release of neurotransmitters after a stroke. The controlled regulation of its activity thus opens up a promising strategy for novel therapies.READ MORE
Stem Cell Signaling Drives Mammary Gland DevelopmentNews
New research illuminates the biology of breast tissue development and may pave the way to new strategies for diagnosing or even treating cancer.READ MORE
Colon Cancer Cells Use RNA Strands to Evade Cell DeathNews
Researchers have discovered how unusually long strands of RNA, termed “long non-coding RNAs” or lincRNAs, help colon cancer cells avoid death, allowing unregulated growth. A new study showed some lincRNAs could be targeted by drug developers.READ MORE